Availability of technology for managing cancer patients in the Southeast European (SEE) region.
Cancer patients
Cancer registries
Diagnostic equipment
Radiation therapy equipment
SEE region
SEEIIST
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
20
02
2022
accepted:
13
03
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
The Southeast European (SEE) region of 10 countries and about 43 million people differs from Western Europe in that most SEE countries lack active cancer registries and have fewer diagnostic imaging devices and radiotherapy (RT) units. The main objective of this research is to initiate a common platform for gathering SEE regional cancer data from the ground up to help these countries develop common cancer management strategies. To obtain detailed on-the-ground information, we developed separate questionnaires for two SEE groups: a) ONCO - oncologists regarding cancer treatment modalities and the availability of diagnostic imaging and radiotherapy equipment; and b) REG - national radiation protection and safety regulatory bodies regarding diagnostic imaging and radiotherapy equipment in SEE facilities. Based on responses from 13/17 ONCO participants (at least one from each country) and from 9/10 REG participants (all countries but Albania), cancer incidence rates are higher in those SEE countries that have greater access to diagnostic imaging equipment while cancer mortality-to-incidence (MIR) ratios are higher in countries that lack radiotherapy equipment. By combining unique SEE region information with data available from major global databases, we demonstrated that the availability of diagnostic imaging and radiotherapy equipment in the SEE countries is related to their economic development. While immediate diagnostic imaging and radiation therapy capacity building is necessary, it is also essential to develop both national and SEE-regional cancer registries in order to understand the heterogeneity of each country's needs and to establish regional collaborative strategies for combating cancer.
Sections du résumé
Background
UNASSIGNED
The Southeast European (SEE) region of 10 countries and about 43 million people differs from Western Europe in that most SEE countries lack active cancer registries and have fewer diagnostic imaging devices and radiotherapy (RT) units. The main objective of this research is to initiate a common platform for gathering SEE regional cancer data from the ground up to help these countries develop common cancer management strategies.
Methods
UNASSIGNED
To obtain detailed on-the-ground information, we developed separate questionnaires for two SEE groups: a) ONCO - oncologists regarding cancer treatment modalities and the availability of diagnostic imaging and radiotherapy equipment; and b) REG - national radiation protection and safety regulatory bodies regarding diagnostic imaging and radiotherapy equipment in SEE facilities.
Results
UNASSIGNED
Based on responses from 13/17 ONCO participants (at least one from each country) and from 9/10 REG participants (all countries but Albania), cancer incidence rates are higher in those SEE countries that have greater access to diagnostic imaging equipment while cancer mortality-to-incidence (MIR) ratios are higher in countries that lack radiotherapy equipment.
Conclusion
UNASSIGNED
By combining unique SEE region information with data available from major global databases, we demonstrated that the availability of diagnostic imaging and radiotherapy equipment in the SEE countries is related to their economic development. While immediate diagnostic imaging and radiation therapy capacity building is necessary, it is also essential to develop both national and SEE-regional cancer registries in order to understand the heterogeneity of each country's needs and to establish regional collaborative strategies for combating cancer.
Identifiants
pubmed: 35345867
doi: 10.1016/j.ctro.2022.03.004
pii: S2405-6308(22)00017-9
pmc: PMC8956881
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57-66Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Adv Radiat Oncol. 2021 Aug 09;6(6):100772
pubmed: 34805620
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Radiother Oncol. 2014 Jul;112(1):140-4
pubmed: 24833561
N Engl J Med. 2013 Oct 3;369(14):1336-43
pubmed: 24088093
Lancet Oncol. 2021 Apr;22(4):e136-e172
pubmed: 33676609
Clin Oncol (R Coll Radiol). 2021 Dec;33(12):e521-e529
pubmed: 34116903
Lancet Oncol. 2013 Apr;14(4):e168-75
pubmed: 23561748
Radiother Oncol. 2016 Apr;119(1):5-11
pubmed: 26922487
Ann Glob Health. 2014 Sep-Oct;80(5):412-7
pubmed: 25512156
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593